PTC Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

PTC Therapeutics kazanç ve gelirinin sırasıyla yıllık 46.3% ve 5.5% oranında artması tahmin edilirken, EPS'nin yıllık 44.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

46.3%

Kazanç büyüme oranı

44.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	5.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:PTCT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	835	-158	94	207	12
12/31/2025	721	-317	22	2	14
12/31/2024	784	-391	-202	-181	14
9/30/2024	901	-453	-274	-178	N/A
6/30/2024	900	-480	-230	-115	N/A
3/31/2024	928	-579	-199	-58	N/A
12/31/2023	938	-627	-279	-158	N/A
9/30/2023	798	-642	-343	-224	N/A
6/30/2023	819	-618	-364	-248	N/A
3/31/2023	770	-571	-403	-289	N/A
12/31/2022	699	-559	-509	-357	N/A
9/30/2022	697	-531	-409	-260	N/A
6/30/2022	618	-556	-422	-273	N/A
3/31/2022	569	-522	-395	-249	N/A
12/31/2021	539	-524	-337	-251	N/A
9/30/2021	492	-455	-327	-247	N/A
6/30/2021	472	-391	-250	-169	N/A
3/31/2021	430	-454	-271	-213	N/A
12/31/2020	381	-438	-250	-194	N/A
9/30/2020	358	-441	-193	-140	N/A
6/30/2020	311	-432	-221	-182	N/A
3/31/2020	322	-292	-198	-138	N/A
12/31/2019	307	-252	-144	-99	N/A
9/30/2019	297	-222	-142	-104	N/A
6/30/2019	279	-213	-116	-85	N/A
3/31/2019	262	-181	-72	-54	N/A
12/31/2018	265	-128	-43	-28	N/A
9/30/2018	256	-78	0	9	N/A
6/30/2018	245	-61	N/A	-10	N/A
3/31/2018	224	-69	N/A	3	N/A
12/31/2017	194	-79	N/A	-10	N/A
9/30/2017	142	-107	N/A	-45	N/A
6/30/2017	123	-108	N/A	-53	N/A
3/31/2017	90	-130	N/A	-91	N/A
12/31/2016	83	-142	N/A	-104	N/A
9/30/2016	70	-166	N/A	-121	N/A
6/30/2016	57	-174	N/A	-124	N/A
3/31/2016	48	-174	N/A	-129	N/A
12/31/2015	37	-170	N/A	-124	N/A
9/30/2015	37	-147	N/A	-102	N/A
6/30/2015	29	-131	N/A	-91	N/A
3/31/2015	24	-118	N/A	-80	N/A
12/31/2014	25	-94	N/A	-57	N/A
9/30/2014	17	-84	N/A	-64	N/A
6/30/2014	32	-62	N/A	-52	N/A
3/31/2014	37	-51	N/A	-53	N/A
12/31/2013	35	-66	N/A	-47	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PTCT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: PTCT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: PTCT önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: PTCT şirketinin gelirinin (yıllık 5.5% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PTCT şirketinin gelirinin (yıllık 5.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PTCT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

PTC Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 8.4% to US$45.00

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Recent updates

Price target increased by 8.4% to US$45.00

PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023